Key result
Based on a review of five publications, tamoxifen used concurrently with other QT-prolonging agents is likely of low risk for causing clinically significant QT prolongation at 20 mg daily.
Why the study?
Does tamoxifen increase the risk of clinically significant QT prolongation when used concurrently with other QT-prolonging agents?
Does tamoxifen increase the risk of clinically significant QT prolongation when used concurrently with other QT-prolonging agents?
Despite being flagged by drug information sources, tamoxifen at standard doses appears to carry a low risk of clinically significant QT prolongation even when combined with other QT-prolonging medications.
No takes yet. Share an insight, caveat, or question.
Reassures on low QT risk with standard-dose tamoxifen plus other agents; challenges flagged interactions and extends limited safety data.
Fung et al. (2017) conducted a review in QT prolongation. Tamoxifen was evaluated on Clinically significant QT-prolonging event. Based on a review of five publications, tamoxifen used concurrently with other QT-prolonging agents is likely of low risk for causing clinically significant QT prolongation at 20 mg daily.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: